CJC-1295 — Advanced Growth Hormone Research Peptide

Growth Hormone Signaling | GHRH Receptor Research | IGF-1 Regulation | Endocrine Research

Product Overview

CJC-1295 is a synthetic peptide analogue of Growth Hormone-Releasing Hormone (GHRH), developed to investigate the stimulation of endogenous growth hormone (GH) secretion and its downstream effects on insulin-like growth factor 1 (IGF-1).

CJC-1295 interacts with GHRH receptors in the anterior pituitary gland, stimulating the body's growth hormone signaling system rather than acting as externally administered growth hormone.

The compound has attracted scientific interest in endocrinology, growth hormone regulation, metabolic physiology, and age-related hormonal research.

Although frequently discussed in connection with muscle development, fat metabolism, physical recovery, and healthy aging, these potential benefits have not been established through adequate clinical efficacy trials.

Mechanism of Action

CJC-1295 acts through the GHRH signaling pathway, which plays an essential role in regulating endogenous growth hormone secretion.

• GHRH Receptor Activation: Stimulates receptors in the anterior pituitary gland involved in growth hormone release.

• Growth Hormone Secretion: Clinical research has demonstrated increased circulating GH concentrations following exposure to the long-acting form of CJC-1295.

• IGF-1 Regulation: Increased GH signaling can stimulate hepatic and peripheral production of IGF-1, an important mediator of growth hormone activity.

• Hormonal Pulsatility: Research has investigated whether the natural pulsatile pattern of GH secretion is maintained during prolonged GHRH receptor stimulation.

• Endocrine Signaling: Provides an experimental model for investigating interactions between pituitary hormone secretion, metabolism, and growth-related biological pathways.

CJC-1295 Variants: DAC vs. Non-DAC

Two peptide formulations are commonly discussed in the research peptide market, although their scientific nomenclature and clinical evidence differ.

Characteristic	CJC-1295 with DAC	CJC-1295 without DAC
Alternative Name	Long-acting CJC-1295	Modified GRF (1-29)
Structure	GHRH analogue incorporating a Drug Affinity Complex	Short-acting modified GHRH analogue
Duration of Action	Prolonged	Shorter
Albumin Binding	Designed for extended binding to circulating albumin	Does not contain the DAC modification
Human Research	Limited controlled pharmacokinetic and pharmacodynamic studies	Very limited direct human clinical evidence
Primary Research Focus	Sustained GH and IGF-1 signaling	Short-duration GHRH receptor signaling

Scientific Clarification: The term “CJC-1295 without DAC” is commonly used commercially for Modified GRF (1-29). These formulations should not be considered interchangeable, and clinical findings from the DAC-containing compound cannot automatically be applied to the non-DAC version.

Clinical Research & Scientific Findings

Early human research involving long-acting CJC-1295 demonstrated measurable changes in growth hormone and IGF-1 concentrations.

In a published clinical investigation involving healthy adults:

• Mean circulating GH concentrations increased approximately 2- to 10-fold after a single administration.

• Mean circulating IGF-1 concentrations increased approximately 1.5- to 3-fold.

• The estimated elimination half-life was approximately 5.8–8.1 days.

• Sustained hormonal effects were observed during the study period.

These findings demonstrate pharmacological activity but do not establish improvements in muscle growth, body composition, exercise recovery, sleep quality, or longevity.

Potential Research Applications

1. Growth Hormone Regulation

Investigation of endogenous GH secretion and the biological mechanisms controlling pituitary hormone release.

2. IGF-1 Signaling

Exploration of GH-dependent IGF-1 production and its role in cellular growth, tissue regulation, and endocrine physiology.

3. Skeletal Muscle Research

Examination of GH/IGF-1 signaling pathways associated with muscle protein metabolism and tissue adaptation.

4. Adipose Tissue & Metabolic Research

Investigation of interactions between growth hormone signaling, lipid metabolism, and body composition.

5. Recovery & Tissue Physiology

Research into the biological roles of GH and IGF-1 in tissue turnover and repair mechanisms.

6. Sleep & Age-Related Endocrine Research

Exploration of relationships between growth hormone secretion, sleep physiology, and age-related hormonal changes.

These are experimental research areas rather than clinically established benefits of CJC-1295.

Research Involving Ipamorelin

CJC-1295 is sometimes discussed alongside Ipamorelin, a growth hormone secretagogue that acts through a different receptor system.

• CJC-1295: Targets the GHRH receptor signaling pathway.

• Ipamorelin: Acts primarily through the growth hormone secretagogue receptor (GHSR-1a).

The combination is of experimental interest because the two substances influence distinct pathways associated with GH secretion.

However, controlled clinical evidence establishing the safety, efficacy, or therapeutic superiority of this combination is insufficient.

Safety & Potential Adverse Effects

CJC-1295 remains an investigational peptide without established approval for routine clinical use in the European Union.

Reported or potential adverse effects include:

• Injection-site reactions

• Flushing and vasodilatory reactions

• Increased heart rate

• Headaches or dizziness

• Fluid retention

• Possible alterations in glucose regulation and insulin sensitivity

• Potential complications associated with increased GH/IGF-1 signaling

Long-term safety, immunogenicity, and possible risks associated with sustained hormonal stimulation remain insufficiently characterized.

The complete safety profile of CJC-1295, particularly for prolonged exposure or combination with other growth hormone secretagogues, has not been established.

Scientific Evidence & Limitations

Although early human studies have demonstrated increases in GH and IGF-1 concentrations, important limitations remain:

• No established clinical evidence of meaningful muscle hypertrophy.

• No conclusive evidence of sustained fat loss.

• No proven anti-aging or longevity benefits.

• Insufficient evidence supporting improved athletic performance or recovery.

• Limited long-term safety data.

• Lack of adequate controlled human studies for commonly marketed non-DAC formulations.

Research Use Only

FOR SCIENTIFIC AND LABORATORY RESEARCH PURPOSES ONLY.

Intended exclusively for qualified professionals conducting legitimate scientific investigations in endocrinology, peptide pharmacology, and metabolic research.

Not approved for general human or veterinary use. Not intended for personal injection, self-administration, bodybuilding enhancement, or unauthorized therapeutic applications.

Not intended to diagnose, treat, cure, or prevent any disease.

Research-use labeling does not constitute authorization for clinical administration or commercial distribution as an approved medicinal product.

PEPTITAN — PRECISION. SCIENCE. RESEARCH.